Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1977 1
1983 2
1984 1
1987 2
1988 1
1990 2
1994 2
1997 1
1998 1
1999 2
2000 2
2002 1
2003 1
2004 2
2005 2
2006 5
2007 4
2008 4
2009 3
2010 5
2013 1
2014 3
2015 1
2016 4
2018 4
2019 3
2020 7
2021 2
2022 4
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

72 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Junctional epidermolysis bullosa gravis of Herlitz"
Page 1
Gene Therapy for Epidermolysis Bullosa.
Marinkovich MP, Tang JY. Marinkovich MP, et al. J Invest Dermatol. 2019 Jun;139(6):1221-1226. doi: 10.1016/j.jid.2018.11.036. Epub 2019 May 5. J Invest Dermatol. 2019. PMID: 31068252 Free article. Review.
Epidermolysis bullosa is a family of diseases characterized by blistering and fragility of the skin in response to mechanical trauma. Advances in our understanding of epidermolysis bullosa pathophysiology have provided the necessary foundation for the …
Epidermolysis bullosa is a family of diseases characterized by blistering and fragility of the skin in response to mechanical …
Efficacy and safety of Oleogel-S10 (birch triterpenes) for epidermolysis bullosa: results from the phase III randomized double-blind phase of the EASE study.
Kern JS, Sprecher E, Fernandez MF, Schauer F, Bodemer C, Cunningham T, Löwe S, Davis C, Sumeray M, Bruckner AL, Murrell DF; EASE investigators. Kern JS, et al. Br J Dermatol. 2023 Jan 23;188(1):12-21. doi: 10.1093/bjd/ljac001. Br J Dermatol. 2023. PMID: 36689495 Clinical Trial.
BACKGROUND: Epidermolysis bullosa (EB) is a heterogeneous group of rare, difficult-to-treat, inherited multisystem diseases affecting epithelial integrity. ...EASE was funded by Amryt Research Limited. METHODS: Patients with dystrophic EB, junctional EB or Ki …
BACKGROUND: Epidermolysis bullosa (EB) is a heterogeneous group of rare, difficult-to-treat, inherited multisystem diseases af …
Bullous autoimmune dermatoses.
Hofmann SC, Juratli HA, Eming R. Hofmann SC, et al. J Dtsch Dermatol Ges. 2018 Nov;16(11):1339-1358. doi: 10.1111/ddg.13688. J Dtsch Dermatol Ges. 2018. PMID: 30395395
Depending on the respective target proteins of the autoimmune response and their location in the skin, a distinction is made between intraepidermal (pemphigus disorders), junctional (pemphigoid disorders), and subepidermal (epidermolysis bullosa acquisita, de …
Depending on the respective target proteins of the autoimmune response and their location in the skin, a distinction is made between intraep …
Gene therapy of epidermolysis bullosa.
Bauer JW, Laimer M. Bauer JW, et al. Expert Opin Biol Ther. 2004 Sep;4(9):1435-43. doi: 10.1517/14712598.4.9.1435. Expert Opin Biol Ther. 2004. PMID: 15335311 Review.
Easy access to the organ and identification of underlying mutations in epidermolysis bullosa (EB) facilitated the first cutaneous gene therapy experiments in vitro in the mid-1990s. ...Using this approach, the genotypic and phenotypic hallmark features of the recess …
Easy access to the organ and identification of underlying mutations in epidermolysis bullosa (EB) facilitated the first cutane …
Leading edge: emerging drug, cell, and gene therapies for junctional epidermolysis bullosa.
Keith AR, Twaroski K, Ebens CL, Tolar J. Keith AR, et al. Expert Opin Biol Ther. 2020 Aug;20(8):911-923. doi: 10.1080/14712598.2020.1740678. Epub 2020 Mar 20. Expert Opin Biol Ther. 2020. PMID: 32178539 Free PMC article. Review.
INTRODUCTION: Junctional epidermolysis bullosa (JEB) is a rare inherited genetic disorder with limited treatments beyond palliative care. ...Current clinical trials use topical drug delivery to manipulate the inflammation and re-epithelialization phase …
INTRODUCTION: Junctional epidermolysis bullosa (JEB) is a rare inherited genetic disorder with limited treatments beyon …
Gene therapies for inherited skin disorders.
Abdul-Wahab A, Qasim W, McGrath JA. Abdul-Wahab A, et al. Semin Cutan Med Surg. 2014 Jun;33(2):83-90. doi: 10.12788/j.sder.0085. Semin Cutan Med Surg. 2014. PMID: 25085667 Review.
Preclinical studies have shown impressive results in terms of gene correction using both in vivo and ex vivo approaches. The clinical application of gene replacement or genomic editing as potential therapies for inherited skin disorders, however, has been held back by the …
Preclinical studies have shown impressive results in terms of gene correction using both in vivo and ex vivo approaches. The clinical …
Attenuation of Severe Generalized Junctional Epidermolysis Bullosa by Systemic Treatment with Gentamicin.
Hammersen J, Neuner A, Wild F, Schneider H. Hammersen J, et al. Dermatology. 2019;235(4):315-322. doi: 10.1159/000499906. Epub 2019 May 27. Dermatology. 2019. PMID: 31132778
Severe generalized junctional epidermolysis bullosa (JEB), a lethal genodermatosis, is mainly caused by premature termination codons (PTCs) in one of the three genes encoding the anchoring protein laminin-332. ...This retrospective study aimed at assessing fo …
Severe generalized junctional epidermolysis bullosa (JEB), a lethal genodermatosis, is mainly caused by premature termi …
Birch Bark Extract: A Review in Epidermolysis Bullosa.
Heo YA. Heo YA. Drugs. 2023 Sep;83(14):1309-1314. doi: 10.1007/s40265-023-01935-z. Epub 2023 Sep 2. Drugs. 2023. PMID: 37658982 Review.
Birch bark extract (Filsuvez(); also known as the developmental name Oleogel-S10), a topical gel consisting of 10% dry birch bark extract and 90% sunflower oil, is the first therapy approved in the EU and UK for the treatment of partial thickness wounds associated with dystrophic …
Birch bark extract (Filsuvez(); also known as the developmental name Oleogel-S10), a topical gel consisting of 10% dry birch bark extract an …
Skin-Derived ABCB5(+) Mesenchymal Stem Cells for High-Medical-Need Inflammatory Diseases: From Discovery to Entering Clinical Routine.
Niebergall-Roth E, Frank NY, Ganss C, Frank MH, Kluth MA. Niebergall-Roth E, et al. Int J Mol Sci. 2022 Dec 21;24(1):66. doi: 10.3390/ijms24010066. Int J Mol Sci. 2022. PMID: 36613507 Free PMC article. Review.
A range of preclinical studies has suggested therapeutic efficacy of ABCB5(+) MSCs in a variety of currently uncurable skin and non-skin inflammatory diseases, which has been substantiated thus far by distinct clinical trials in chronic skin wounds or recessive dystrophic …
A range of preclinical studies has suggested therapeutic efficacy of ABCB5(+) MSCs in a variety of currently uncurable skin and non-skin inf …
Cholinergic control of epidermal cohesion.
Grando SA. Grando SA. Exp Dermatol. 2006 Apr;15(4):265-82. doi: 10.1111/j.0906-6705.2006.00410.x. Exp Dermatol. 2006. PMID: 16512874 Review.
The components of the KC ACh axis are involved in cutaneous blistering in patients with autoimmune pemphigus, junctional and dystrophic forms of epidermolysis bullosa, thermal burns, and mustard-induced vesication. ...
The components of the KC ACh axis are involved in cutaneous blistering in patients with autoimmune pemphigus, junctional and dystroph …
72 results